Neurocrine Biosciences (NASDAQ: NBIX) reported Q1 EPS of $0.49, $0.05 worse than the analyst estimate of $0.54. Revenue for the quarter came in at $236.6 million versus the consensus estimate of $252.55 million.

For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.